EWTX insider trading
NasdaqGS HealthcareEdgewise Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Company website: edgewisetx.com
EWTX insider activity at a glance
FilingIQ has scored 257 insider transactions for EWTX since Mar 30, 2021. The most recent filing in our index is dated May 5, 2026.
Across the full history, 20 open-market purchases
and 124 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on EWTX insider trades is 62.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest EWTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding EWTX
Frequently asked
- How many insider trades does FilingIQ track for EWTX?
- FilingIQ tracks 257 Form 4 insider transactions for EWTX (Edgewise Therapeutics, Inc.), covering filings from Mar 30, 2021 onwards. 13 of those were filed in the last 90 days.
- Are EWTX insiders net buyers or net sellers?
- Across the full Form 4 history for EWTX, 20 transactions (8%) were open-market purchases and 124 (48%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EWTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is EWTX in?
- Edgewise Therapeutics, Inc. (EWTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.43B.
Methodology & sources
Every EWTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.